Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3160-3166

  Hudes, Gary ^a   Einhorn, Lawrence ^a   Ross, Eric ^a   Balsham, Andrew ^a   Loehrer, Patrick ^a   Ramsey, Harry ^a   Sprandio, John ^a   Entmacher, Michael ^a   Dugan, William ^a   Ansari, Rafat ^a   Monaco, Frank ^a   Hanna, Mark ^a   Roth, Bruce ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

EID: 0032886933     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3160     Document Type: Article

References (27)

1. Wingo PA, Landis S, Ries LAG: An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 47:239-242, 1997
2. Dahllof B, Billstron A, Cabral F, et al: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53:4573-4581, 1993
3. Speicher LA, Laing N, Barone LR, et al: Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol 46:866-872, 1994
4. Tew KD, Glucker JP, Hartley-Asp B, et al: Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther 56:323-339, 1992
5. Yogada A, Smith JA, Soloway MD, et al: Phase II study of estramustine phosphate in advanced hormone-refractory prostate cancer with increasing prostate specific antigen levels. J Urol 145:384A, 1991 (abstr)
6. Tew KD, Stearns ME: Estramustine: A nitrogen mustard/steroid with antimicrotubule activity. Pharmacol Ther 43:299-319, 1989
7. Mareel MM, Storme GA, Dragonetti CH, et al: Anti-invasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro. Cancer Res 48:1842-1849, 1988
8. Speicher LA, Sheridan VR, Godwin AK, et al: Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype. Br J Cancer 64:267-273, 1991
9. Amato RJ, Logothetis CJ, Dexeus FH, et al: Preliminary results of phase II trial of estramustine and vinblastine for patients with progressive hormone-refractory prostate carcinoma. Proc Am Soc Clin Oncol 7:207, 1988 (abstr)
10. Seidman A, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial endpoint for hormone-refractory prostate cancer. J Urol 147:931-934, 1992
11. Hudes GH, Greenberg R, Krigel R, et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992
12. Dexeus F, Logothetics CJ, Samuels ML, et al: Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 69:885-886, 1985
13. Ware JE, Kosinski M, Keller SD: SF-36 Physical and Mental Summary Scales: A User's Manual. Boston, MA, The Health Institute, 1994
14. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
15. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Schoenfeld DA, Richter JR: Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38:163-170, 1982
17. Daponte D, Sylvester R, DePauu M, et al: Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol Br J Urol 65:408-4112, 1983
18. Hudes GR: Estramustine-based chemotherapy. Semin Urol Oncol 15:13-19, 1997
19. VanPoppel H, Werbrook PW, Baert L: Effect of estramustine phosphate on free androgens. Acta Urol Belg 58:89-95, 1990
20. Tannock IF, Osoba D, Stockier MR, et al: Mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1756-1764, 1996
21. Kantoff PW, Conaway M, Weiner E, et al: Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: Preliminary results from a prospective randomized Cancer and Leukemia Group B Study (9182) comparing chemotherapy to best supportive care. J Clin Oncol 14:1743, 1996 (abstr 2013)
22. Small EJ, Marshall ME, Leyno L, et al: Superiority of suramin + hydrocortisone over placebo + hydrocortisone: Results of a multicenter double blind Phase III study in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 17, 1998 (abstr 1187)
23. Hudes GR, Nathan F, Khater C, et al: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156-3163, 1997
24. Kreis W, Budman DR, Fetten J, et al: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone-refractory prostate carcinoma. Ann Oncol 10:33-38, 1999
25. Petrylak DP, Macarthur RB, O'Connor J, et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967, 1999
26. Wilson L, Jordan MA: Microtubule dynamics: Taking aim at a moving target. Curr Biol 2:569-573, 1995
27. Panda D, Miller HP, Islam K, et al: Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action. Proc Natl Acad Sci USA 94:10560-10564, 1997